The Liver Meeting
October 29 - November 2
Welcome to the HCV Advocate’s AASLD Conference coverage. In an effort to best serve our readership, we will post all the important and interesting abstracts about HCV from the conference. While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted. The other abstracts posted to the web site are HCV related abstracts posted to www.aasld.org that we have not been able to report on or update.
To locate specific abstracts on this page, click on “Edit” at the top of your browser (Microsoft Internet Explorer) and then on Find (on this page). In Netscape, click on “Search” and then on “Find in This Page.” Simply type in a word or term and the search engine will list the related abstracts.
Please click here to view our fact sheet on reading and understanding an abstract.
Acute Hepatitis C - Treatment
Diagnostic Tools –
· COMPARISON OF REAL TIME PCR (TAQMAN) ROCHE AND VERSANT HCV RNA BAYER FOR HCV RNA USING THE INTERNATIONAL UNIT STANDARD: IMPLICATIONS FOR MANAGEMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION IN CLINICAL PRACTICE
· DIAGNOSTIC VALUE OF BIOCHEMICAL MARKERS, FIBROTEST-ACTITEST-HCV-FIBROSURE (FT-AT) COMPARED WITH SERUM PROTEIN PROFILING BY SELDI-TOF PROTEINCHIP (STP), FOR THE DIAGNOSIS OF BRIDGING FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C
· FIBROSCAN® IS A NEW NON INVASIVE METHOD FOR THE DETECTION OF CIRRHOSIS AND ITS COMPLICATIONS IN PATIENTS WITH CHRONIC LIVER DISEASES. RESULTS OF A PROSPECTIVE STUDY IN 456 PATIENTS (updated 11/1/2004)
· LARGE SCALE STUDIES USING NON-INVASIVE BIOCHEMICAL MARKERS OF LIVER INJURY, FIBROTEST-ACTITEST-HCV-FIBROSURE® (FT-AT): THE LOW NEGATIVE PREDICTIVE VALUE OF TRANSAMINASES IN AGED PATIENTS WITH CHRONIC HEPATITIS C (updated 11/7/2004)
Predicting Treatment Response–
Quality of Life–
Side Effect Management